Maddogrel (Clopidogrel)

Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor, which stops ADP‑mediated activation of the glycoprotein IIb/IIIa complex. This inhibition prevents platelets from aggregating and forming clots, thereby reducing the risk of arterial thrombosis.

The dosage of Maddogrel is determined by the prescribing clinician based on the individual patient's clinical condition, renal function, and concomitant therapies. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for clopidogrel in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Maddogrel, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maddogrel (clopidogrel) is a thienopyridine that provides irreversible P2Y12 inhibition, whereas agents such as aspirin act on cyclo‑oxygenase‑1 and ticagrelor offers reversible P2Y12 blockade. Clinical choice depends on efficacy, bleeding risk, drug‑drug interactions and patient‑specific factors.

Maddogrel tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Maddogrel is taken orally, usually with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe or uncontrolled bleeding (including gastrointestinal, intracranial, or ocular hemorrhage), thrombotic thrombocytopenic purpura, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice unusual bruising, blood in stools or urine, or severe skin reactions.

Maddogrel is contraindicated in patients with active pathological bleeding, a known hypersensitivity to clopidogrel or any component of the formulation, and in those who have severe hepatic impairment. Caution is also advised for individuals with a history of stroke or intracranial hemorrhage.